Drug Development Pharma - January 19, 2018
New receptors found for Follicum’s lead candidate
New research has identified receptors in human hair follicle cells that its lead candidate FOL-005 binds to. The newly acquired knowledge paves the way for a better understanding of how FOL-005 can be used for treatment of hair loss, and a significant milestone in the continued development of FOL-005, reports the company. “The positive news […]
Drug Development Pharma - January 11, 2018
AstraZeneca’s Fasenra receives EU approval
The European Commission has approved Fasenra (benralizumab) as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta-agonists. Their first respiratory biologic medicine The approval is based on the results from the WINDWARD programme, including the pivotal Phase III exacerbation trials, SIROCCO and CALIMA, and the Phase III OCS-sparing trial, ZONDA. […]
Drug Development Pharma - January 3, 2018
FDA accepts AZ’s regulatory submission for Tagrisso
The company announced before christmas that the US Food and Drug Administration has accepted a supplemental New Drug Application (sNDA) for the use of Tagrisso (osimertinib), a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with clinical activity against central nervous system (CNS) metastases, in the 1st-line treatment of patients with metastatic non-small cell […]
Drug Development Pharma - December 7, 2017
InDex Pharmaceuticals announces new scientific data
InDex Pharmaceuticals Holding has announced new scientific data on the mechanism of action of cobitolimod, the company’s lead drug candidate. The findings show that cobitolimod can modulate the immune system in ulcerative colitis by balancing the mucosal Th17/Treg cell response. Cobitolimod has demonstrated clinical efficacy and a favourable safety profile in inducing clinical remission in […]
Business article - November 30, 2017
Antibiotic advances from New Drugs 4 Bad Bugs
Public-private partnerships are addressing the major challenges of microbial drug resistance. In 2016, a woman in the United States died from a bacterial strain resistant to 26 antibiotics. Recently, The Lancet reported on a dangerously resistant strain in China. The World Health Organization says that antimicrobial resistance (AMR) is a global emergency. Countering this worrying trend is the public-private program New Drugs 4 Bad Bugs […]
Drug Development Pharma - November 23, 2017
Beactica awarded 2 MSEK funding
Beactica has been awarded 2 MSEK by the Swedish Governmental Agency for Innovation Systems (Vinnova) to advance its LSD1 programme. The LSD1 programme aims to develop a novel class of compounds with the potential to radically improve the current treatment of glioblastoma, an aggressive brain tumour with 40 000 annual cases in the EU and the […]
